XXXX in preventing @entity1211 after arthroplastic surgery in Taiwan.

@entity1 @entity548 @entity6950 @entity3925 @entity572 @entity1031 @entity2720 @entity715 @entity1211
@entity1211 ( @entity1211 ) is one of the severe complications of @entity572 ( @entity572 ) and total knee arthroplasty (TKA). The incidence of @entity1211 could be reduced if preventive antithrombotic medicines are used; however, the incidence of @entity548 may increase. @entity3925 is a factor Xa inhibitor that prevents @entity1211 after @entity572 or TKA. This study is designed to confirm the efficacy and safety of @entity3925 in Taiwan. This is a retrospective database study based on the data of 6996 @entity1 provided by the Taiwan National Health Insurance Research Database from 2008 to 2012. The data included the number of prescription, the cost of prescription, and case number for @entity1 treated with antithrombotic agents for the prevention or @entity2720 (including @entity572 , TKA, partial hip arthroplasty, revision @entity572 and TKA), and the incidence of @entity715 and @entity548 from year 2008 to 2012. The overall postoperative @entity1211 rate was 0.49%. Compared with other antithrombotic drugs, @entity3925 and @entity6950 analogs can reduce the percentage of @entity715 . We also found that the expenditure and hospitalization was less in the @entity3925 group than in the @entity6950 analogs group. Because some benefits of @entity3925 were found in our study, further cost-effective and drug safety studies are warranted. It is important to consider the cost-effective principle for the use of antithrombotic drugs in preventing @entity1031 after @entity2720 .
